Atorvastatin, typically used as a hypolipidemic agent, was found in one study to mitigate lung fibrosis by lowering CTGF expression in a mouse model of bleomycin‐induced lung fibrosis.83 Here, CCN2 is linked to pulmonary fibrosis.